Acne Vulgaris clinical trials

Explore recruiting acne vulgaris clinical trials.

Recruiting acne vulgaris studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Acne Vulgaris trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase 2 randomized, double blind, placebo-controlled study to evaluate the safety and efficacy of topical AT-004 1% in the participants with acne vulgaris.

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase III study to assess efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel 5%, applied once daily for 12 weeks in patients with acne vulgaris (GEDACNE-1)

Spain, Italy, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase III study to assess efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel 5%, applied once daily for 12 weeks in patients with acne vulgaris (GEDACNE-2)

Italy, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A long-term safety and efficacy study of N-Acetyl-GED-0507-34-LEVO gel 5%, in subjects with acne vulgaris (GEDACNE-LT)

Italy, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, randomized, double-blind, parallel, three-arm, active- and placebo-controlled therapeutic equivalence study for the comparison of clindamycin + tretinoin/Verisfield gel (1+0.025)% with Acnatac®/Meda gel [clindamycin + tretinoin (1+0.025)%] in the treatment of acne vulgaris.

Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

Acne Vulgaris trials by city

Acne Vulgaris in Toronto Acne Vulgaris in Vancouver Acne Vulgaris in Montreal Acne Vulgaris in Calgary Acne Vulgaris in Edmonton Acne Vulgaris in Ottawa Acne Vulgaris in Winnipeg Acne Vulgaris in Quebec City Acne Vulgaris in Hamilton Acne Vulgaris in Kitchener Acne Vulgaris in London Acne Vulgaris in Halifax Acne Vulgaris in New York Acne Vulgaris in Los Angeles Acne Vulgaris in Chicago Acne Vulgaris in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease